Sarah Cannon Research Institute (SCRI) offers clinical trials in communities close to home, where 85% of patients seek care.
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportThe US Oncology Network embraces value-based care.
Read time: 4.5 minutes
In the traditional healthcare payment model, a patient visits a provider who then bills for the specific services rendered. Each additional service—perhaps another checkup, scan, or infusion—results in another itemized bill being generated. While this fee-for-service model might seem logical enough, it may result in more tests and other billable services with limited value instead of emphasizing what really matters most: providing patients with the best possible care.
“Historically, we’ve lived in a fee-for-service world, but all the major payers desire fee-for-value,” says Lalan Wilfong, MD, vice president of payer relations and practice transformation for The US Oncology Network (“The Network”), an association of independent oncology practices that is supported by McKesson. With this newer approach, providers focus on providing better value for patients with reimbursement for enhanced patient care.
So-called value-based care isn’t a totally new concept to members of The Network, which has long been helping providers deliver value-based, integrated cancer care for more than a decade. And 14 practices in The Network have been participating in the Oncology Care Model (OCM), a pilot program formed in 2016 that was designed by the Centers for Medicare & Medicaid Innovation to provide higher quality, more coordinated cancer care for the same or lower cost.
Practices that have joined the OCM program commit to several core “redesign” activities aimed at improving care while providing optimal patient experience. Upon joining the OCM program, participating practices reflected on their existing protocols and modified them as needed with an eye on closing gaps necessary to improve patient outcomes. They also agreed to provide 24/7 access to care, expand patient navigation tools and follow nationally recognized clinical guidelines for cancer treatment.
“Oncology is complex because you’re dealing with high-risk patients who need prompt, quality care,” says Stuart Staggs, senior director of strategic programs for The Network. “That’s why it is important to eliminate any barriers that might get in the way of treating a patient, which in many ways is at the heart of any value-based care model.”
One example of a simple change made that had significant impact was the expansion of the “call us first” program. In the past, patients with cancer who felt ill after-hours were generally advised to go to the emergency room, which was difficult for patients and expensive. Since joining the OCM, providers advised patients to contact them first, no matter the day or time.
“The goal was to manage a patient’s urgent care issues in the practice when appropriate rather than send them to the ER,” says Staggs. “Clinicians also reached out to patients more proactively. We wanted to catch problems before they became more acute and try to decrease avoidable hospitalizations.”
Practices also began integrating services such as mental health, social work, navigation, and nutrition counseling for cancer into their offices, rather than referring patients to outside providers.
Meanwhile, employees at each oncology practice clarified their own roles to optimize workflows and make sure that nothing was falling through the cracks. “Pre OCM, physicians would educate patients in the manner in which they saw fit. Some were giving out paperwork about diagnosis and treatment options, whereas some were delegating to advanced practice providers or nurses,” says Dr. Wilfong.
Under the OCM, roles were solidified: The oncologists took charge of discussing treatment options with patients, a crucial part of shared decision making. Once a treatment plan was in place, pharmacists provided instruction on at-home drug administration while nurses and advanced practice providers educated patients on medication side effects, infusion timing, and quality of life. Financial counselors provided any necessary guidance related to financial obligations, and administrative staff made a concerted effort to minimize appointment wait times. Some of these things were happening before, but “we clarified who does what so that patients would have a more uniform experience,” says Dr. Wilfong.
Also crucial: ensuring that patients and doctors were on the same page so that patients felt well-informed about their choices and knew what to realistically expect from their treatment. “Value doesn’t mean cheap or even low cost,” says Dr. Wilfong. “To me, value-based care is about aligning treatment with patient goals,” which entails providing the best treatment for the patient at the lowest cost” in terms of toxicity as well as price.
There’s little doubt that such changes benefitted patients. By December 2020, four and a half years into the OCM, participating practices reported an average 37% decrease in patient hospitalizations and a 24% decrease in emergency department visits. Pain management scores and rates of depression screening also improved.
What’s more, these and other improved metrics translated to a $240 million cumulative savings to Medicare to date while enabling 11 of the 14 practices to receive performance-based payments, thanks to meeting OCM quality and cost goals. Performance-based payments reward practitioners for meeting specific pre-determined goals.
Perhaps most importantly, says Dr. Wilfong, is that patient feedback has been excellent. “We were able to reduce hospitalization and emergency department visits and save money, and patient satisfaction remained high. All in all, we drove value back to our patients.”
The first phase of this OCM program officially ends this summer, and what happens next will be up to the Centers for Medicare & Medicaid Innovation. “They will likely be launching another model and though we don’t yet know the specifics, we can maintain a state of preparedness by continuing to implement much of what we learned,” says Dr. Wilfong. “Patients appreciate the changes this model has driven. They now expect to have shared-decision making and enhanced services provided to them.”
Sarah Cannon Research Institute (SCRI) offers clinical trials in communities close to home, where 85% of patients seek care.
Sarah Cannon Research Institute (SCRI) offers clinical trials in communities close to home, where 85% of patients seek care.
How Shenandoah Oncology became a blueprint for compassion and turned patient feedback into a lifeline.
How Shenandoah Oncology became a blueprint for compassion and turned patient feedback into a lifeline.
How community oncology clinics are helping break down barriers to care.
How community oncology clinics are helping break down barriers to care.
Designed to be the premier annual event for community oncology, the conference brought together a diverse audience of physicians, clinicians, administrators, industry leaders and biopharma representatives.
Designed to be the premier annual event for community oncology, the conference brought together a diverse audience of physicians, clinicians, administrators, industry leaders and biopharma representatives.
How Sarah Cannon Research Institute’s clinical trials changed Mike’s cancer journey.
How Sarah Cannon Research Institute’s clinical trials changed Mike’s cancer journey.
How Biopharma and community oncology are working together to solve healthcare’s toughest challenges and build a more resilient future for cancer care.
How Biopharma and community oncology are working together to solve healthcare’s toughest challenges and build a more resilient future for cancer care.
Meeting the demands of ultra-sensitive treatments with purpose-built storage, automation and pharmacy integration
Meeting the demands of ultra-sensitive treatments with purpose-built storage, automation and pharmacy integration
In the third episode of our Always Advancing video series, learn how precision and personalized medicine are transforming cancer care – expanding access to clinical trials and novel treatments in communities.
In the third episode of our Always Advancing video series, learn how precision and personalized medicine are transforming cancer care – expanding access to clinical trials and novel treatments in communities.
Using McKesson Compile’s analytics to transform how patients with rare blood disorders access specialized care across Indiana.
Using McKesson Compile’s analytics to transform how patients with rare blood disorders access specialized care across Indiana.
InspiroGene by McKesson helps patients with rare and severe diseases access innovative cell and gene therapies through personalized support at every step of their journey.
InspiroGene by McKesson helps patients with rare and severe diseases access innovative cell and gene therapies through personalized support at every step of their journey.